Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patie
Go back to Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patie| AbbVie (NYSE: ABBV) | Delayed: 264.48 +0.52 (0.20%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $263.96 | 52 Week High | $68.12 | |||
| Open | $263.07 | 52 Week Low | $50.71 | |||
| Day High | $266.60 | P/E | 57.37 | |||
| Day Low | $261.23 | EPS | $4.61 | |||
| Volume | 3,434,901 | |||||
